Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02504216 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 6,564
- Enrollment target
NCT02504216: Completed Phase 3 study, sponsored by Bayer.
NCT02504216 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 6,564 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (750% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02504216, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 6,564 participants
- Enrollment target
Study Summary
The purpose of study was to test whether rivaroxaban added to standard of care treatment, when compared to placebo, had the potential to reduce the incidence of the clinical events related to the clots and complications of the heart and brain (CV death, MI, or stroke) or the legs (acute limb ischemia or major amputation) in patients who had undergone recent procedure(s) to improve the blood flow of their legs.
Primary Outcome
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.
Interventions
- DRUG Rivaroxaban (Xarelto, BAY59-7939)
- DRUG Rivaroxaban-Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,564 participants |
| Start Date | 2015-08-18 |
| Est. Completion | 2020-01-09 |
| Phase | Phase 3 |
What the finished NCT02504216 record still lists
NCT02504216 is an interventional study that assigns participants to a tested intervention. Its 6,564 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (750% higher).
The record links to 0 conditions, and to 2 interventions - of which Rivaroxaban (Xarelto, BAY59-7939) is the first listed.
NCT02504216 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02504216 about?
NCT02504216 is a clinical study titled "Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities". The purpose of study was to test whether rivaroxaban added to standard of care treatment, when compared to placebo, had the potential to reduce the incidence of the clinical events related to the clots and complications of the heart and brain (CV death, MI, or stroke) or the legs (acute limb ischemi...
What is the current status of trial NCT02504216?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 6,564 participants. The study started on 2015-08-18. Estimated completion is 2020-01-09.
What interventions are being tested in trial NCT02504216?
The interventions under investigation include: Rivaroxaban (Xarelto, BAY59-7939) (DRUG), Rivaroxaban-Placebo (DRUG).
Who is sponsoring clinical trial NCT02504216?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02504216's enrollment target sits among peer trials
6,564 35th of 2000 higher than 1,966 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05143697 · 6,600 participants · NA
Motivational Wellness Coaching to Reduce Childhood Obesity in Families and Kids
- NCT05515224 · 6,600 participants · NA
5-Cog 2.0: A Pragmatic Clinical Trial
- NCT05369429 · 6,516 participants · NA
My Wellbeing Guide: a Novel Tool for Managing Stress and Improving Quality of Life
- NCT06272045 · 6,618 participants · NA
Early Intervention to Promote Cardiovascular Health of Mothers and Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI